Axoltis Pharma is developing NX210c, a groundbreaking treatment for Amyotrophic Lateral Sclerosis (ALS, also known as maladie de Charcot in French), the most frequent of the rare diseases and one of the most devastating. ALS progressively destroys motor neurons, leading to muscle weakness, paralysis, and ultimately death, with very limited treatment options today.

NX210c is the first targeted – and most advanced – treatment addressing this high unmet medical need. This peptide restores the blood-brain barrier (BBB), a key factor in ALS, Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. With 7 patents and orphan drug designation in the USA and EU for ALS, NX210c has shown an excellent tolerability profile and is currently being evaluated in a Phase 2 clinical trial on 80 patients, with topline results expected in April 2026.

Axoltis, nominated for the prestigious Prix Galien, is a pioneer in BBB restoration and is accelerating the development of NX210c, bringing new hope to millions of patients facing neurodegenerative diseases.

Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. The lead program of Nicox’s ophthalmic pipeline, NCX 470, has successfully completed Phase 3 clinical development targeting glaucoma in the U.S. and China, with a separate Phase 3 program ongoing in Japan.

Their ophthalmic pipeline also includes a candidate under preclinical evaluation for development in retinal conditions, NCX 1728. Nicox has two products which are commercialized in the U.S.; VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024% and ZERVIATE® (cetirizine ophthalmic solution) 0.24%, for use in patients with open-angle glaucoma and ocular allergic conjunctivitis respectively. ZERVIATE is also commercialized in China.

Kahimmune is a next generation biotech company pioneering the re exploration of the cancer immunopeptidome to develop synergistic, mRNA-based companion neoantigen therapies (CNT). By deeply mining the “dark genome” through its innovative proprietary platform, Kahinomics™, Kahimmune uncovers novel neoantigens designed to power innovative combination strategies in oncology.

SITERA Pharmaceuticals is a next-generation biotech company focused on a highly dynamic and largely untapped central platform in neuroscience: The Mitochondrial-ER Associated Membranes (MAMs). This platform serves as a key hub in the regulation of cellular metabolism, stress, and neuronal survival. By leveraging its proprietary technology platform, which combines cutting-edge chemical and biological expertise, SITERA design powerful, selective, and safe small molecule therapeutics that are capable of restoring impaired cellular functions in pathological contexts. The company is thus able to adress challenging central nervous system diseases and potentially provide clinical solutions and benefit for patients having rare and less rare neurodegenerative diseases with urgent and unmet medical needs.

Cevidra is an independent French pharmaceutical company with 20 years of experience supporting the availability of essential, niche, and innovative medicines in France. Headquartered in Grasse, with a second entity in Lyon, Cevidra provides international biotech and pharmaceutical companies with a fully integrated local platform combining pharmaceutical exploitation, regulatory operations, market access, early access, compassionate access, pharmacovigilance coordination, quality oversight, and hospital distribution.

Cevidra operates through two complementary business models.

First, Cevidra commercializes hospital medicines with marketing authorization in France through a purchase-and-resale model. This approach is particularly suited for international companies seeking a reliable French partner to manage local exploitation, distribution, hospital access, supply operations, and post-authorization commercialization without establishing their own affiliate in France. Cevidra can act as the French exploitant and distributor, ensuring that medicines are made available to hospitals in compliance with French pharmaceutical and regulatory requirements.

Second, Cevidra supports innovative biotech companies from post-Phase 2b development onwards by helping them generate earlier revenue and provide French patients with access to the latest therapeutic innovations before full commercial launch. Through French early access and compassionate access pathways, Cevidra enables companies developing promising therapies, particularly in rare diseases, oncology, hematology, immunology, infectious diseases, and advanced therapies, to treat patients with high unmet medical needs while preparing their future market entry. This model can include regulatory strategy, early access submissions, data collection, hospital implementation, distribution, pricing and reimbursement support, and transition planning toward post-marketing authorization commercialization.

Cevidra’s main differentiation lies in its responsiveness, operational flexibility, and integrated “all under one roof” model. As both a pharmaceutical exploitant and hospital distributor, Cevidra can coordinate the key activities required to make a medicine available in France, from regulatory and quality requirements to logistics, hospital supply, pharmacovigilance interface, and market access support. This structure reduces complexity for international partners and provides a single accountable French point of contact.

Cevidra combines deep knowledge of the French healthcare system with a network of European partners, enabling companies to build a pragmatic and scalable access strategy. Its independence, long-standing experience, and hands-on approach make Cevidra a trusted partner for companies looking to enter or expand in the French hospital pharmaceutical market.

BIOPHTA’s new standard of care offers a non-invasive, 7‑day topical microdosing, to provide a continuous therapeutic exposure for replacing injections or daily eyedrops. This scalable platform offers a transformative solution to poor adherence, burden and pain of injections, as well as inconsistent outcomes.

OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and immuno-inflammation.

OSE Immunotherapeutics has a dynamic partnership business model based on innovative products that generates non-dilutive revenues and finances R&D programs. These products have real blockbuster potential and give to OSE-Immunotherapeutics, an ability to conclude global agreements at different stages of their development with major pharmaceuticals players. OSE-Immunotherapeutics actively seeks international partners for out-Licencing of compounds at all stages of clinical development of drug products.

Cilcare is a French-US biopharmaceutical company pioneering auditory science, developing innovative drugs and diagnostics to prevent and treat hearing disorders. The company addresses a major unmet medical need worldwide: hearing loss, which is expected to affect nearly 2.5 billion people by 2050. Growing evidence identifies hearing loss as the leading modifiable risk factor for dementia. Through its integrated platform spanning therapeutic development, translational research, and AI-driven auditory analytics, Cilcare is committed to making hearing a global health priority and advancing precision medicine for patients worldwide.

Cilcare’s lead drug candidate, CIL001, targets cochlear synaptopathy, an early stage of hearing loss affecting an estimated 15% of the global population. It is characterized by difficulty understanding speech in noisy environments. This condition, which can be worsened by noise exposure, Alzheimer’s and Parkinson’s disease, may progress to more severe hearing loss if left untreated.

Founded in 2014 by three visionary women entrepreneurs, Cilcare is headquartered in France, with laboratories in Montpellier and Boston, and offices in Paris and Tokyo. The company employs a team of 50 international collaborators, supported by a scientific advisory board and surrounded by the most renowned experts (KOLs) in auditory science. With a strong track record of strategic partnerships with major players worldwide, Cilcare has established itself as a global leader in auditory science.

Enemsa Pharma is a drug discovery company developing high‑impact combination therapies for intractable neurodegenerative and cardiopulmonary diseases—where monotherapies have failed. Inspired by breakthrough successes in oncology and infectious diseases, they target the untapped potential of multi‑mechanism approaches in complex disorders. Their strategy centers on modulating the Integrated Stress Response (ISR), a core cellular survival pathway implicated in many diseases.

Enemsa Pharma’s lead asset, icerguastat, is a clinically validated ISR modulator with Phase 1 completed. By sustaining the protective stress response, icerguastat prevents stress‑induced cell death and serves as a de‑risked backbone for first‑ or best‑in‑class synergistic combinations with approved or standard‑of‑care therapies. Their lead ongoing development program is icerguastat + ambroxol for Parkinson’s disease patients carrying GBA1 mutations, the most common genetic form of PD. This platform unlocks new IP, accelerates partnering, and aims to deliver transformative outcomes for patients with the highest unmet medical needs.

Ceres Brain Therapeutics is a biotechnology company advancing CBT101, a novel central nervous system (CNS) therapeutic candidate that has recently progressed into Phase 2 clinical development. CBT101 is positioned to address major unmet needs in severe neurological diseases through a differentiated, indication specific approach to neuronal energy dysfunction.

CBT101 is being developed in amyotrophic lateral sclerosis (ALS), a rapidly progressive and fatal neurodegenerative disease with limited treatment options, as well as in creatine transporter deficiency (CTD), a rare paediatric neurological disorder with no effective disease modifying therapies. While based on a single molecular entity, CBT101 applies distinct mechanistic rationales aligned with each indication: targeting neuronal and mitochondrial energy dysfunction in ALS, and restoring intracellular creatine availability in neurons in CTD.

The program is supported by robust non clinical data and early clinical evidence demonstrating central nervous system activity and target engagement in humans. CBT101 is delivered as a non invasive nasal spray, offering a clear advantage in terms of patient convenience and treatment burden compared with injectable or hospital based therapies.

To support ongoing Phase 2 development and pipeline expansion, Ceres Brain Therapeutics is currently seeking to raise USD 20 million and is actively exploring strategic partnership opportunities, including co‑development, licensing, and regional collaborations, to accelerate development and maximize the value of CBT101 across its neurological indications.